Intraperitoneal chemotherapy: a prolonged infusion of 5-fluorouracil using a novel carrier solution.
A novel carrier solution, icodextrin 20 (7.5%) has allowed exploration of prolonged intraperitoneal (IP) infusion of the cytotoxic drug, 5-fluorouracil. Eighteen patients with intraperitoneal carcinomatosis were entered into a feasibility and pharmacokinetic study of prolonged regional (IP) chemotherapy.. Specialist nurses trained the patients to self-administer their own treatment via a permanent i.p. catheter. A twin bag delivery system was used to perform one exchange daily. It proved possible to deliver continuous (5 days per week) i.p. 5-fluorouracil at doses of 200 mg/m2 and 300 mg/m2 for up to 12 weeks. The toxicities seen were infective peritonitis, nausea and vomiting, lethargy and anorexia. This was a nurse-led study and the home-based therapy holds promise for patients with malignant peritoneal disease.
Young
A
A
Gilbert
J
J
Sherman
M
M
Chatwin
D
D
Budden
J
J
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D015314:Dialysis Solutions / Q000627:therapeutic use*; D004337:Drug Carriers; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000379:methods / Q000451:nursing; D010534:Peritoneal Neoplasms / Q000188:drug therapy*
D000964:Antimetabolites, Antineoplastic; D015314:Dialysis Solutions; D004337:Drug Carriers; D005472:Fluorouracil